Faeth Therapeutics, Inc. Shareholders' Equity
Faeth Therapeutics, Inc. (FTH) had Shareholders' Equity of $172.96 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $172.96M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$137.29M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $18.59M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $23.01M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $172.96M 10-Q · filed 2026-08-04 |
| 2026-03-31 | -$137.29M 10-Q · filed 2026-08-04 |
| 2025-12-31 | $18.59M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $23.01M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $27.31M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $31.99M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $38.39M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $45.78M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $52.19M 10-Q · filed 2025-11-14 |
| 2024-03-31 | $58.47M 10-Q · filed 2025-11-14 |
| 2023-12-31 | $64.89M 10-K · filed 2026-03-30 |
| 2023-09-30 | $71.00M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $79.20M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $94.85M 10-Q · filed 2024-11-14 |
| 2022-12-31 | $103.41M 10-K · filed 2025-03-28 |
| 2022-09-30 | $113.99M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $125.92M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $135.31M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $146.51M 10-K · filed 2024-02-29 |
| 2021-09-30 | $155.21M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $163.13M 10-Q · filed 2022-11-08 |
| 2021-03-31 | $171.25M 10-Q · filed 2022-11-08 |
| 2020-12-31 | -$56.44M 10-K · filed 2023-03-29 |
| 2020-09-30 | -$51.68M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$47.09M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$42.89M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$68.66M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |